Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who finished their last round of nerve-damaging chemotherapy at least three months ago
- People who have reported a moderate or higher level of numbness and tingling (a score of 2 or more out of 4 on a standard symptom questionnaire) in the past week
- People who can speak and read English
- People who have access to the internet
Who may not be able to join:
- People who had nerve damage (peripheral neuropathy) from any cause before this study
- People who are planning to start taking duloxetine (a medication sometimes used for chemotherapy-related nerve pain) for the first time during the study period
- People who are already taking part in another trial that is focused on managing symptoms that could affect nerve-related side effects
- People who have a high-grade inflammatory condition such as lupus, Crohn's disease, or rheumatoid arthritis
- People who regularly take anti-inflammatory medications (such as ibuprofen or naproxen) or steroid supplements
- People who eat an average of three or more servings of fish per week, or who take daily fish oil capsules containing EPA and DHA, or who take daily flaxseed oil capsules
- People who eat fewer than five servings per week of sweet foods or sugary drinks — such as lollies, chocolate, doughnuts, cookies, cakes, ice cream, pastries, soft drinks, or sweetened coffee or tea (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recruitment of all participants (Feasibility); Completion of baseline and 12-week patient-reported outcome measures (Feasibility); Percent of LASO-3 participants who attend at least 5 out of 8 intervention sessions (Feasibility); Percent of LASO-3 participants who self-report adherence to dietary goals (Feasibility)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.